Metagenomi, Inc. Board of Directors

Metagenomi, Inc., a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases. It has a development, option, and license agreement with Affini-T Therapeutics, Inc. to develop and commercialize gene edited T-cell receptor-based therapeutic products in the field of treatment, prevention, or diagnosis of human cancer; and a collaboration and license agreement with Ionis Pharmaceuticals, Inc. to research, develop, and commercialize investigational medicines using genome editing technologies. The company was incorporated in 2016 and is based in Emeryville, California.

Dr. Brian Charles Thomas Ph.D.

Dr. Brian Charles Thomas Ph.D.

Co-Founder, CEO & Chairman of the Board

Mr. Matthew L. Wein J.D.

Mr. Matthew L. Wein J.D.

Vice President of Corporate Legal, Compliance & Corporate Secretary

Mr. Simon Harnest M.Sc.

Mr. Simon Harnest M.Sc.

Chief Investment Officer & Senior VP of Investor Relations

Dr. Alan Brooks Ph.D.

Dr. Alan Brooks Ph.D.

Senior Vice President of Preclinical

Dr. Joseph Knowles M.D.

Dr. Joseph Knowles M.D.

Co-Founder & Member of Scientific Advisory Board

Dr. Jian Irish M.B.A., Ph.D.

Dr. Jian Irish M.B.A., Ph.D.

President, COO & Director

Leaving Board of Directors Review Your about to visit the following url Invalid URL

Loading...
Comments


Comment created.